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A B S T R A C T
Objective: To investigate expression of BcL-2, FAS, FAS ligand (FASL) and cleaved caspase-3 in the
endometrial tissue of women with idiopathic infertility (with two consecutive failed cycles of in vitro
fertilization) and women with idiopathic recurrent pregnancy loss. The control group consisted of fertile
women.
Study design: Endometrial tissue samples from fertile women (n = 25), women with idiopathic infertility
(n = 25) and women with idiopathic recurrent pregnancy loss (n = 25) were collected on the seventh or
eighth postovulatory day of their menstrual cycles for evaluation. Expression of BcL-2, FAS, FASL and
cleaved caspase-3 was assessed using immunohistochemical methods.
Results: Expression of BcL-2 and FAS was signiﬁcantly higher and lower, respectively, in the women with
idiopathic infertility than in the other groups (p < 0.01). Expression of cleaved caspase-3 was
signiﬁcantly lower in the women with idiopathic infertility than in the other groups (p < 0.01).
Expression of FASL was similar in all three groups.
Conclusion: Disturbances in endometrial apoptosis may be a contributing factor in patients with
idiopathic infertility and recurrent pregnancy loss.
 2012 Elsevier Ireland Ltd. 
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Infertility is deﬁned as one year of frequent unprotected
intercourse that does not result in pregnancy. According to data
from the National Survey of Family Growth, an estimated 10–15%
of couples in the USA are infertile [1]. Idiopathic infertility is
diagnosed when a couple does not conceive and no deﬁnitive
causes of infertility can be diagnosed following a complete
evaluation. Despite improved diagnostic techniques, the average
incidence of idiopathic infertility has been reported to be
approximately 15% in infertile couples [2], with a range of 0.1–
37% [3–9]. Conventional treatments have not been effective in
some cases of idiopathic infertility [9,10], and these patients were
not able to conceive following these procedures [9,10]. It is
important to understand the potential changes in endometrial* Corresponding author at: Rua Sena Madureira, 1245 Ap 11, Sa˜o Paulo, SP 04021-
051, Brazil. Tel.: +55 11 5081 3681; fax: +55 11 5081 3681.
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Open access under the Elsevier OA license. physiology, particularly following the failure of consecutive cycles
of in vitro fertilization (IVF), in cases of idiopathic infertility.
Idiopathic recurrent pregnancy loss is a serious reproductive
problem. Most of these losses occur at the time of implantation,
and 15–20% of cases end in spontaneous abortion. Recurrent
pregnancy loss is deﬁned as at least three consecutive mis-
carriages, and represents a frustrating clinical challenge for both
clinicians and patients. Recurrent pregnancy loss affects 0.5–3% of
women of reproductive age. Approximately 50% of recurrent
pregnancy losses are idiopathic [11,12].
The human endometrium has the unique ability to undergo
extensive and rapid remodelling [13]. It is fascinating to study, and
has been used to understand normal and pathological uterine
functions and as a model for rapid tissue remodelling events, such
as embryonic development, tumorigenesis and wound healing.
As a mucosal tissue, the endometrium provides defence against
infection [13]. It has a unique immunological capability that allows
implantation of a semi-allogeneic embryo [14,15]. During the
process of implantation, cellular differentiation and changes in the
extracellular matrix and endometrial apoptosis may be important
[16,17]. Apoptosis is regulated by various gene products, including
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and inhibitors of apoptosis have been described. Tumour necrosis
factor-a and the FAS/FAS ligand (FASL) system have been shown to
promote apoptosis [18], while BcL-2 appears to inhibit the process
[19–27]. Several studies have suggested that apoptosis of human
endometrial glandular cells is blocked by BcL-2 expression during
the proliferative phase, and is induced by the FAS/FASL system in
an autocrine or paracrine manner during the secretory phase. In
general, downstream signalling of the FAS/FASL system in human
endometrial glandular cells is inﬂuenced by cleaved caspase-3,
which represents an irreversible step during apoptosis [24].
Information regarding this process during the embryo implanta-
tion window is scarce, particularly in cases of idiopathic infertility
and recurrent pregnancy loss.
2. Materials and methods
Between October 2004 and February 2007, 160 women were
recruited as volunteers to participate in this study at the
Gynaecology Endocrinology Outpatient Clinic at the Federal
University of Sa˜o Paulo, Sa˜o Paulo, Brazil. Written informed
consent was obtained from the participants, and the local ethics
committee approved the study.
Case histories, complete physical and gynaecological examina-
tions, transvaginal pelvic and complete abdominal ultrasonogra-
phies, and laboratory and hormone tests were performed. The
women with idiopathic infertility had previously undergone a
laparoscopy that did not reveal any signs of endometriosis or other
anatomical disorders that could explain their infertility. All
potential participants underwent a standard diagnostic work-up
to rule out veriﬁable causes of recurrent pregnancy loss or
idiopathic infertility prior to inclusion in the study. Diagnostic
procedures included hysterosalpingography, hysteroscopy, pater-
nal and maternal karyotypes, cervical cultures for chlamydia,
ureaplasma and mycoplasma, a comprehensive hormonal status
[oestradiol, progesterone, testosterone, 17-hydroxyprogesterone,
dehydroepiandrosterone, androstendione, follicle-stimulating
hormone (FSH), luteinizing hormone (LH), thyroid-stimulating
hormone (TSH), free T4 and prolactin], evaluation of antipho-
spholipid syndrome using IgM and IgG anticardiolipin antibodies,
and lupus anticoagulant testing. Blood was collected to test for
toxoplasmosis, listeriosis, brucellosis, rubeola, cytomegalovirus,
hepatitis (B and C), human immunodeﬁciency virus and VDRL (for
syphilis). The exclusion criteria included: diabetes or high blood
levels of fasting glucose (>110 mg/dl); anaemia (low levels of
haematoglobin); leukocytes; liver and kidney disturbances;
systemic arterial hypertension; a history of abnormal menses,
anovulation or endometriosis (or high levels of CA-125); luteal
body insufﬁciency; or other endocrinological disturbances. Wom-
en with endometrial tissues that were histologically incompatible
with the secretory phase were also excluded from this study.
To avoid confounding factors due to ethnicity, only caucasian
women were included in this study. Women with parents of the
same ethnicity were included to avoid confounding factors due to
genetic admixture.
In total, 75 volunteers were selected and divided into three
groups of 25 women: (a) fertile women with at least two normal
pregnancies and no history of infertility (control group); (b)
women with idiopathic recurrent pregnancy loss; and (c) women
with idiopathic infertility and two consecutive failed IVF cycles.
The speciﬁc inclusion criteria for each group were as follows:
control group, at least two consecutive pregnancies and labours
without any history of infertility or pregnancy loss; women with
idiopathic recurrent pregnancy loss, a documented history (based
on ultrasound examination) of at least three spontaneous
consecutive miscarriages prior to 20 weeks of gestation with thesame partner; and women with idiopathic infertility, a documen-
ted history of infertility with at least two consecutive failed IVF
cycles using good-quality embryos (e.g. at least two embryos with
eight cells (Grade 4) on the third day of embryonic life). The
partners of the women with idiopathic infertility and recurrent
pregnancy loss were normospermic and presented with negative
semen and urethral cultures. The exclusion criteria in these two
groups included the presence of thrombophilic factors (e.g. PT
mutation G20210A, AT-III, R506Q mutation of Factor V Leiden,
proteins C and S, lupus anticoagulant and anticardiolipin
antibodies).
On the second clinic visit, patients underwent endometrial
biopsies using a Pipelle catheter (Unimar, Bridgeport, CT, USA)
under sterile conditions to remove tissue from the uterine fundus
during the seventh or eighth postovulatory day of their menstrual
cycles. Extreme care was taken to ensure that a sufﬁcient tissue
sample was obtained from each biopsy. The sample was ﬁxed in
10% formalin and processed for histological evaluation using
haematoxylin–eosin (H–E), and immunohistochemical analysis of
BcL-2, FAS, FASL and cleaved caspase-3.
For endometrial dating, 4 mm sections stained with H–E were
evaluated. All of the endometrial biopsies were coded, and
evaluated blindly by an experienced pathologist according to
the histopathological criteria of Noyes et al. [28]. If the samples
were not compatible with the secretory phase, the tissues were not
included for immunocytochemical analysis.
All endometrial samples investigated in the study were tested
using: mouse monoclonal antibody FAS (B-10, Santa Cruz
Biotechnology, Santa Cruz, CA, USA; dilution 1:50), rabbit
polyclonal FASL (N-20, Santa Cruz Biotechnology; dilution 1:50),
a BcL-2 oncoprotein kit [Dako, 124, MxH (M0887-1)], and cleaved
caspase-3 (Asp175) (Antibody #9661, Cell Signaling Technology,
Beverly, MA, USA; dilution 1:200).
The biopsy samples were embedded in parafﬁn and cut into 4 mm
sections. The sections were dewaxed in Bioclear (Bio-Optica, Milan,
Italy) and rehydrated in decreasing concentrations of ethanol
followed by distilled water. Sections were pretreated in a 0.01 mol/l
citrate buffer (Merck, USA) in a microwave oven (700 W) for two
incubations of 12 min each and cooled at room temperature for
20 min. The slides were rinsed with Tris-buffered saline.
Endogenous peroxidases were blocked using 3% hydrogen
peroxide in methanol for 10 min. The sections were washed in
phosphate buffered saline (PBS), covered in 100 ml of blocking
serum, and incubated for 30 min. The sections were incubated
overnight with the primary antibody at 4 8C in PBS buffer with 1%
bovine serum albumin (Sigma A 9647, USA). After washing with
PBS buffer, localization of the antibodies was visualized by
incubating the sections with secondary antibodies using a Dako
kit (Dako LSAB + Sys, Peroxidase Universal K0690-1). After 30 min
of incubation followed by washing, the sections were incubated
with a freshly prepared solution of streptavidin-biotin immuno-
peroxidase (Dako LSAB kit) according to the protocol provided by
the manufacturer. After washing, the bound enzyme was visual-
ized following incubation with the enzyme in the presence of 3,3-
diaminobenzidine tetrahydrochloride (Dako K3468-1), 1% DMSO
(Synth, Brazil) and 0.06% hydroxide peroxide in 100 ml of PBS
buffer for 5 min at 37 8C in a dark room. The slides were washed in
PBS with 0.1% Triton X-100. The sections were counterstained with
haematoxylin and dehydrated prior to mounting with Entellan
(Merck 107961, Germany). Palatine tonsil tissue and BcL-2 were
positive controls for FAS/FASL/cleaved caspases-3 and BcL-2,
respectively. Bovine serum albumin was substituted for the
primary antibody and used as a negative control. Other negative
controls were applied using non-speciﬁc goat antibodies with the
same concentration of primary antibody for each immunohisto-
chemical reaction (BcL-2, FAS, FASL and cleaved caspase-3).
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cells were present after immunostaining. The total score was based
on the percentage of positive epithelial cells and the degree of
immunostaining intensity.
The percentage of positive epithelial cells was graded as
follows: no stained cells (Grade 0), 1–25% stained cells (Grade 1),
26–50% stained cells (Grade 2), 51–75% stained cells (Grade 3), and
76–100% stained cells (Grade 4) in the representative ﬁeld [29].
The approximate percentage of immunopositive cells was esti-
mated based on 10 representative ﬁelds. The immunostaining
intensity was scored as negative (0), weak (1), moderate (2) or
strong/intense (3) [30]. Three experienced observers who were
blinded to the purpose of the slides performed all of the
assessments. After completion of the study, the same observers
re-examined the slides to ensure reproducibility of the semiquan-
titative assessment. The total index was calculated using the
following formula: total index = [percentage of positive
cells]  [immunostaing intensity].
The results of all of the analyses were expressed as the mean
and standard error of the mean and were analysed using two-way
analysis of variance and Tukey–Kramer multiple comparisons. A
signiﬁcance level of 5% (a) was adopted for all tests. The
descriptive level (p) was calculated and presented for all of the
statistics. The power analysis assumed a clinically meaningful
difference for four points between the three groups with respect to
the primary endpoint. Under these assumptions, at least 22 women
were required for 95% power.
3. Results
Table 1 shows the clinical characteristics of the women
included in this study. There were no signiﬁcant differences in
age between the groups, and no differences in the volunteers’ age
at ﬁrst menstruation or their ﬁrst experience of intercourse. All of
the volunteers had regular 28.4 (0.88)-day cycles. Abnormal
uterine bleeding was not identiﬁed in any of the women. There were
no signiﬁcant differences in terms of body mass index. The Ferriman
and Gallwey index was never more than seven for any of the
participants. Hypertension (>140/90 mmHg) was not detected. The
average number of gestations was higher in the control group and the
women with recurrent pregnancy loss than the women with
idiopathic infertility. The number of miscarriages, however, was
signiﬁcantly higher in the women with recurrent pregnancy loss, and
the number of times a patient had been in labour was higher in the
control group. The serum CA-125 levels and ultrasound data
(performed on the day of the endometrial biopsy) of the participants
were grouped together. No signiﬁcant differences in CA-125 levels
(expressed in U/ml) were identiﬁed between the groups. The ovarianTable 1
Clinical, laboratory and ultrasound data on the study participants (mean  standard err
Control group Women 
recurren
Age (years) 31.04  0.77 28.58  0
Age at menarche (years) 12.96  0.47 12.65  0
Age at ﬁrst coitus (years) 17.71  0.60 18.04  0
Gestations 2.54  0.17 3.46  0
Live births 2.33  0.09 – 
Miscarriages 0.21  0.10 3.46  0
Body mass index 22.91  15.12 22.62  1
CA-125 (U/ml) 16.32  1.54 15.58  1
Uterine volume (ml) 80.83  5.06 54.75  2
Right ovary volume (ml) 7.67  0.46 6.74  0
Left ovary volume (ml) 7.17  0.43 6.93  0
Endometrial echo (mm) 8.06  0.28 7.73  0
Transvaginal sound was performed during the secretory phase. Analysis of variance anvolume (right and left ovaries) and the endometrial echo via
transvaginal ultrasound did not reveal any signiﬁcant differences
between the groups. Signs of ovulation were detected in all of the
patients using serial ultrasound. Uterine volume was greater in the
control group than the other groups. None of the women presented
with solid images or complex cysts in both ovaries.
Table 2 shows the hormone concentrations of the participants.
No signiﬁcant differences were detected in oestradiol and
progesterone levels in the ﬁrst phase of the cycle, or the FSH,
LH, prolactin, TSH and free T4 levels in the second phase. Patients
with hormonal discordance between ultrasonographic and histo-
logical analyses were not excluded from this study.
Figs. 1 and 2 show the immuno-expression levels of BcL-2, FAS,
FASL and cleaved caspase-3 in the three groups. The women with
idiopathic infertility had the highest expression of BcL-2 compared
with the other groups, and the lowest expression of FAS and
cleaved caspase-3. No signiﬁcant differences in expression of FASL
were observed between the groups.
4. Comment
This study investigated the expression of BcL-2, FAS, FASL and
cleaved caspase-3 in the endometrium of women with idiopathic
infertility and recurrent pregnancy loss. The results indicate that
women with idiopathic infertility may have lower expression of
FAS and higher expression of BcL-2, which suggests a decrease in
apoptotic signalling mechanisms in the epithelial cells during the
implantation window. A possible explanation for the observed
results may be increased potential for infertile women to resist
apoptosis. As embryo invasion is a dynamic process that involves
cell proliferation and degradation, it may be a disadvantage for
cells to respond with late onset or a lowered capacity for the
necessary physiological process of apoptosis. This may explain the
difﬁculty experienced by some women in achieving a successful
pregnancy [25,26].
FAS and FASL are known to participate in apoptosis. FASL plays a
crucial role in development of the normal immune system, and the
maintenance, regulation and function of homeostasis. This protein
binds with the FAS (CD95) receptor on the surface of sensitized
cells to induce cell death [14]. The induction of FAS-mediated
apoptosis is immunologically important, and dysfunction of
apoptosis may contribute to the development of several auto-
immune diseases [15,16] and various malignant neoplasms [17–
19]. Although the details regarding the downstream signalling of
the FAS/FASL system in human endometrial glandular cells during
the menstrual cycle remain unknown, several studies have shown
that caspase-8 may be activated by the FAS/FASL signal, resulting






.91 29.70  1.04 0.17
.28 11.88  0.38 0.14
.52 18.29  0.46 0.73
.15 0.32  0.10 <0.01
–
.15 0.32  0.10 <0.01
4.12 23.88  12.45 0.98
.78 13.80  1.30 0.51
.32 48.75  2.69 <0.01
.39 7.40  0.32 0.04
.28 6.70  0.30 0.63
.10 7.95  0.19 0.50
d Tukey’s test were applied for statistical analysis.
Table 2
Hormonal determinations of participants (mean  standard error).





Oestradiol in ﬁrst phase of menstrual cycle (pg/ml) 43.45  3.88 54.50  4.82 49.09  4.93 0.23
Oestradiol in second phase of menstrual cycle (pg/ml) 224.92  9.27 232.51  15.06 198.98  17.38 0.11
Progesterone in ﬁrst phase of menstrual cycle (ng/ml) 0.77  0.07 0.87  0.09 0.82  0.08 0.78
Progesterone in second phase of menstrual cycle (ng/ml) 16.28  0.83 15.24  0.61 14.35  0.92 0.22
Follicle-stimulating hormone (mIU/ml) 6.83  0.35 7.15  0.54 8.25  0.66 0.09
Luteinizing hormone (mIU/ml) 5.08  0.38 4.76  0.33 4.51  0.35 0.51
Prolactin (ng/ml) 12.09  1.36 12.96  1.16 11.30  1.43 0.55
Thyroid-stimulating hormone (mIU/ml) 2.69  0.24 2.21  0.18 2.29  0.16 0.19
Free T4 (ng/dl) 1.19  0.05 1.27  0.05 1.20  0.06 0.57
Analysis of variance and Tukey’s test were applied for statistical analysis.
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cell death process.
The morphological changes observed in cells undergoing
apoptosis is the ﬁnal result of activation of speciﬁc enzymes
known as ‘‘caspases’’. These enzymes modulate apoptosis and
serve as markers of apoptosis even before morphological signs are
evident. Caspases are responsible for the cleavage of substratesFig. 1. Photomicrographs of endometrial sections after immunostaining. Expression of 
women with idiopathic infertility. Expression of FAS: (D) Gcont; (E) women with idiopath
ligand: (G) control group; (H) women with idiopathic recurrent pregnancy loss; (I) wom
women with idiopathic recurrent pregnancy loss; (L) women with idiopathic inferti
antibodies) of immunohistochemical reactions: (1) BcL-2; (2) FAS; (3) FAS ligand; (4) ccontaining aspartic acid residues, such as poly (ADP-ribose)
polymerase, cell cycle regulatory proteins and structural proteins,
including laminin and actin [26]. Although more than 14 different
caspases have been identiﬁed in humans, some have pro-apoptotic
properties. For example, caspases-1, -4 and -5 are known to be
important in inﬂammation, whereas caspases-2, -3 and -10 are
predominantly (if not exclusively) associated with apoptosis [26].BcL-2: (A) control group; (B) women with idiopathic recurrent pregnancy loss; (C)
ic recurrent pregnancy loss; (F) women with idiopathic infertility. Expression of FAS
en with idiopathic infertility. Expression of cleaved caspase-3: (J) control group; (K)
lity. The numbers represent the respective negative controls (non-speciﬁc goat
leaved caspase-3. Bars = 20 mm; original magniﬁcation 400.
Fig. 2. Graphical representation of total index. (A) BcL-2 expression was signiﬁcantly higher in women with unexplained fertility (GIF) than in the other groups (*p < 0.01); (B)
FAS expression was signiﬁcantly lower in the GIF group than in the other groups (*p < 0.01); (C) FAS ligand expression was similar in all three groups; (D) cleaved caspase-3
expression signiﬁcantly lower in the GIF group compared with the other groups (*p < 0.01). Gcont, control group; GIRM, women with idiopathic recurrent pregnancy loss.
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of irreversible cell death. At this irreversible stage, the cell is
destined for apoptosis [27].
The FAS/FASL system is a factor in immune tolerance at the site
of feto–maternal interaction and has been implicated in implan-
tation and placental development because it regulates trophoblast
invasion and spiral artery remodelling [28]. This system is
important for embryo implantation and development in the
endometrium [29]. Although the function of FAS/FASL was
originally described in the context of lymphocyte-mediated
apoptosis of maternal lymphocytes, FASL was shown to be
expressed in the human placenta and foetal membranes through-
out the gestation period [29]. A reduction in levels of FAS protein
may be involved in the failure of IVF cycles in women with
idiopathic infertility.
In conclusion, to the authors’ knowledge, this is the ﬁrst study
to document the expression of BcL-2, FAS and FASL in women with
idiopathic infertility. Future studies will elucidate the role of
disturbances in BcL-2 and FAS/FASL signalling in the physiological
and pathological mechanisms that trigger apoptosis during
embryo implantation and invasion.
Conﬂict of interest statement
None declared.
Funding sources
This study was supported by FAPESP (Sa˜o Paulo, Brazil) Grant #
2004/01424-0.
References
[1] Mosher WD, Bachrach CA. Understanding U.S. fertility: continuity and change
in the National Survey of Family Growth, 1988–1995. Family Planning Per-
spectives 1996;28:4–12.
[2] Templeton AA, Penney GC. The incidence, characteristics, and prognosis of
patients whose infertility is unexplained. Fertility and Sterility 1982;37:
175–82.[3] Collins JA, Corsignani PG. Unexplained infertility: a review of diagnosis,
prognosis, treatment efﬁcacy and management. International Journal of Gy-
necology and Obstetrics 1992;39:267–75.
[4] Kim HH, Hornstein MD. Unexplained infertility: deﬁning the problem and
understanding study design. In: Diamond MP, DeCherney AH, editors. Infer-
tility and reproductive medicine clinics of North America. Philadelphia: WB
Saunders; 1997. p. 487–500.
[5] Crosignani PG, Collins J, Cooke ID, Diczfalusy E, Rubin B. Recommendations of
the ESHRE workshop on ‘‘Unexplained Infertility’’ Anacapri, August 28–9,
1992. Human Reproduction 1993;8:977–80.
[6] Hull MGR. Effectiveness of infertility treatment: choice and comparative
analysis. International Journal of Gynecology and Obstetrics 1994;47:
99–108.
[7] Dodson WC, Haney AF. Controlled ovarian hyperstimulation and intrauterine
insemination for treatment of infertility. Fertility and Sterility 1991;55:
457–67.
[8] Asch RA, Ellsworth LR, Balmaceda JP, Wong PC. Pregnancy after translaparo-
scopic gamete intra fallopian transfer (GIFT). Lancet 1984;2:1034–5.
[9] Audibert F, Hedon B, Arnal F, et al. Results of IVF attempts in patients with
unexplained infertility. Human Reproduction 1989;4:766–71.
[10] Aboulghar MA, Mansour RT, Serour GI, Sattar MA, Amin Y. Intracytoplasmic
sperm injection and conventional in vitro fertilization for sibling oocytes in
cases of unexplained infertility and borderline semen. Journal of Assisted
Reproduction and Genetics 1996;13:38–42.
[11] Gupta S, Agarwal A, Banerjee J, Alvarez JG. The role of oxidative stress in
spontaneous abortion and recurrent pregnancy loss: a systematic review.
Obstetrical and Gynecological Survey 2007;62:335–47.
[12] Pietrowski D, Bettendorf H, Riener EK, et al. Recurrent pregnancy failure is
associated with a polymorphism in the p53 tumour suppressor gene. Human
Reproduction 2005;20:848–51.
[13] Salamonsen LA, Jones RL. Endometrial remodeling, encyclopedia of hormones.
Oxford: Elsevier Science; 2003, 504-12.
[14] Nagler-Anderson C. Man the barrier! Strategic defences in the intestinal
mucosa. Nature Reviews Immunology 2001;1:59–67.
[15] Pijnenborg R. Implantation and immunology: maternal inﬂammatory and
immune cellular responses to implantation and trophoblast invasion. Repro-
ductive Biomedicine Online 2002;4:14–7.
[16] Loke YW, King A. Human implantation: cell biology and immunology. Cam-
bridge: Cambridge University Press; 1995.
[17] Urban G, Marinoni E, Di Lorio R, Lucchini C, Alo P, Di Tondo U. New placental
factors: between implantation and inﬂammatory reaction. Early Pregnancy
2001;5:70–1.
[18] Walsh AO. Uterine cell death during implantation and early placentation.
Microscopy Research and Technique 1993;25:223–45.
[19] Mor G, Kohen F, Garcia-Velasco J, et al. Regulation of Fas ligand expression in
breast cancer cells by estrogen: functional differences between estradiol and
tamoxifen. Journal of Steroid Biochemistry and Molecular Biology
2000;73:185–94.
[20] Tao XJ, Tilly KI, Maravei DV, et al. Differential expression of members of the
BcL-2 gene family in proliferative and secretory human endometrium:
M.Q. Panzan et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 167 (2013) 47–5252glandular epithelial cell apoptosis is associated with increased expression of
bax. Journal of Clinical Endocrinology and Metabolism 1997;82:2738–46.
[21] Wei P. Fas, FasL, BcL-2, and Bax in the endometrium of rhesus monkey during
the menstrual cycle. Molecular Reproduction and Development 2005;70:
478–84.
[22] Otsuki Y, Misaki O, Sugimoto O, Ito Y, Tsujimoto Y, Akao Y. Cyclic BcL-2 gene
expression in human uterine endometrium during menstrual cycle. Lancet
1994;344:28–9.
[23] Yamashita H, Otsuki Y, Matsumoto K, Ueki K, Ueki M. Fas ligand, Fas antigen
and BcL-2 expression in human endometrium during the menstrual cycle.
Molecular Human Reproduction 1999;5:358–64.
[24] Abe H, Shibata MA, Otsuki Y. Caspase cascade of Fas-mediated apoptosis in
human normal endometrium and endometrial carcinoma cells. Molecular
Human Reproduction 2006;12:535–41.[25] Wilcox AJ, Baird DD, Weinberg CR. Time of implantation of the conceptus and
loss of pregnancy. New England Journal of Medicine 1999;340:1796–9.
[26] Ferreira C da S, Maganhin CC, Simo˜es R dos S, Gira˜o MJ, Baracat EC, Soares Jr JM.
Melatonin: cell death modulator. Revista da Associacao Medica Brasileira
2010;56:715–8.
[27] Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770–6.
[28] Bergh PA, Navot D. The impact of embryonic development and endometrial
maturity on the timing of implantation. Fertility and Sterility 1992;58:
537–42.
[29] Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Fertility and
Sterility 1950;1:3–25.
[30] Eide IP, Isaksen CV, Salvesen KA, et al. Fetal growth restriction is associated
with reduced FasL expression by decidual cells. Journal of Reproductive
Immunology 2007;74:7–14.
